Ribavirin

證據等級: L5

預測適應症: 10 個

Ribavirin: From Hepatitis C to Chronic Hepatitis B Virus Infection

One-Sentence Summary

Ribavirin is a broad-spectrum antiviral nucleoside analog, established as a backbone of pegylated-interferon-based combination therapy for Hepatitis C. The TxGNN model predicts it may be effective for Chronic Hepatitis B Virus Infection with a score of 99.86%; however, the 50 clinical trials and 20 publications retrieved are predominantly HCV-specific, and a fundamental mechanistic concern — ribavirin targets RNA viruses while HBV is a DNA virus — puts this prediction in serious question.

Quick Overview

Item	Content
Original Indication	Hepatitis C (pegylated interferon combination therapy)
Predicted New Indication	Chronic Hepatitis B Virus Infection
TxGNN Prediction Score	99.86%
Evidence Level	L4
Philippines Market Status	✗ Not marketed
Number of Registrations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this Evidence Pack. Based on well-established pharmacology, ribavirin is a synthetic guanosine nucleoside analog that inhibits inosine monophosphate dehydrogenase (IMPDH), depleting intracellular GTP pools and thereby suppressing viral RNA synthesis. This mechanism is highly active against RNA viruses — most prominently HCV — but does not directly target HBV DNA polymerase (a reverse transcriptase), which is the molecular target for standard HBV antivirals such as tenofovir and entecavir.

Hepatitis B and Hepatitis C both cause chronic viral hepatitis with significant liver disease burden, and both have historically been treated with interferon-alpha-based regimens. In the TxGNN knowledge graph, ribavirin sits at a node densely connected to interferon-based hepatitis treatment pathways, which are topologically proximate to HBV disease clusters. This explains the high prediction score — but shared treatment context in a knowledge graph does not translate to direct anti-HBV efficacy. The 50 retrieved clinical trials illustrate this problem clearly: not a single trial tests ribavirin specifically against HBV monoinfection.

There is one narrow clinical scenario where ribavirin has intersected with HBV: patients co-infected with both HCV and HBV, where PegIFN + Ribavirin is deployed to treat the HCV component, sometimes resulting in indirect modulation of HBV replication. Notably, a 2000 editorial in the Journal of Gastroenterology directly questioned whether ribavirin is effective for chronic HBV — more than two decades later, this question remains unanswered because supporting evidence never materialized. The current standard of care for chronic HBV (nucleos(t)ide analogs) does not include ribavirin.

Clinical Trial Evidence

⚠️ Important: None of the 50 retrieved trials evaluate ribavirin as primary treatment for HBV monoinfection. All trials are HCV-specific. NCT02339337 is the only trial that enrolled HBV co-infected subjects.

Trial Number	Phase	Status	Enrollment	Key Findings
NCT02339337	Phase 4	Completed	203	Tailored PegIFN + Ribavirin in HCV/HBV dual-infected patients (HBeAg-negative); the sole retrieved trial enrolling HBV-positive subjects; genotype-guided vs. fixed-duration therapy
NCT00215891	Phase 3	Completed	300	PEG-Intron + Ribavirin for chronic HCV in HIV-coinfected patients; comparing 48 vs. 72 weeks of therapy for sustained virologic response (SVR)
NCT00100659	Phase 3	Completed	114	PegIFN alfa-2a ± Ribavirin in pediatric chronic HCV; established safety and efficacy profile in children
NCT01425203	Phase 3	Completed	238	Boceprevir + PegIFN alfa-2b + Ribavirin for HCV genotype 1 in Russian population; treatment-naïve and prior-failure patients
NCT00703118	Phase 3	Completed	663	Telaprevir (two regimens, with and without delayed start) + PegIFN + Ribavirin for chronic HCV GT1 after prior treatment failure
NCT00048724	Phase 3	Completed	631	PEG-Intron maintenance vs. no treatment for HCV-related compensated cirrhosis in patients unresponsive to IFN + Ribavirin
NCT00575224	Phase 4	Completed	60	Pegasys + Copegus (ribavirin) for Asian patients with HCV genotypes 6, 7, 8, and 9; comparing 24- vs. 48-week duration
NCT00237484	Phase 3	Completed	89	Infliximab induction + PegIFN/Ribavirin for HCV genotype 1 patients with elevated TNF-α; evaluating immune modulation on SVR
NCT01529073	Phase 2	Unknown	45	PegIFN + Ribavirin + Nitazoxanide for HCV genotype 4 / HIV co-infection; antiviral activity vs. historical PegIFN + RBV cohort
NCT00720434	Phase 2	Completed	35	PF-00868554 (HCV NS5B polymerase inhibitor) + PegIFN + Ribavirin; standard-of-care combination as treatment backbone

Literature Evidence

PMID	Year	Type	Journal	Key Findings
10832679	2000	Editorial/Review	J Gastroenterol	Directly poses “Is ribavirin treatment really effective for chronic hepatitis B?” — evidence was inconclusive in 2000; no robust anti-HBV activity was demonstrated
32664198	2020	Review	Viruses	HCV/HBV co-infection management: PegIFN + Ribavirin recommended for HCV-RNA-positive co-infected patients; now largely superseded by DAA-based regimens
24659886	2014	Review	World J Gastroenterol	Updates on dual HCV/HBV treatment; viral load dynamics determine treatment prioritization; ribavirin relevant only for the HCV component
27433078	2016	Review	World J Gastroenterol	IFN-α ± ribavirin as prototype HCV/HBV therapy; transition to DAAs; ribavirin explicitly lacks standalone anti-HBV activity
18804888	2008	Review	J Hepatol	“Treatment of HBV/HCV co-infection: still a challenge”; ribavirin deployed only for the HCV component of co-infection management
19669238	2009	Review	Hepatol Intl	Dual HBV/HCV infection: viral interactions and clinical management; PegIFN + RBV indicated only when HCV is the dominant active virus
25048716	2015	Review	Hepatology	Immunological basis of antiviral therapy for HBV and HCV; interferon-stimulated genes as treatment predictors; ribavirin discussed exclusively in HCV context
17009938	2006	Review	Expert Rev Anti-Infect Ther	Treatment options for chronic HBV and HCV in children; IFN-α (without ribavirin) is the backbone for pediatric HBV therapy; ribavirin confined to HCV arm
11160766	2001	Review	Annu Rev Med	Treatment strategies for chronic HBV and HCV; clearly separates IFN + lamivudine for HBV from IFN + Ribavirin for HCV — distinct therapeutic paradigms
15864105	2005	Review	Curr Opin Infect Dis	HBV and HCV infections in children; natural history and therapy; ribavirin role confined to HCV treatment

Philippines Market Information

Ribavirin is not currently registered with the Philippine FDA (0 approved products). There is no local market presence for any ribavirin-containing product.

Safety Considerations

Please refer to the package insert for safety information.

⚠️ Adverse Effect Signal — Hepatic Porphyria (TxGNN Rank #7 Prediction): Analysis of the evidence retrieved for the rank-7 prediction (hepatic porphyria) found 16 publications documenting that PegIFN + Ribavirin combination therapy is a known inducer of Porphyria Cutanea Tarda (PCT), not a treatment for it. The mechanistic direction is reversed: ribavirin/IFN therapy has been shown to trigger porphyrin accumulation, particularly in patients with underlying iron overload or hereditary hemochromatosis variants (HFE H63D). This is an important safety flag — patients with pre-existing hepatic porphyria risk factors should be regarded as a high-risk or contraindicated group if ribavirin were ever to be evaluated for HBV indications.

Conclusion and Next Steps

Decision: Hold

Rationale: The TxGNN prediction score of 99.86% is almost certainly a knowledge graph artifact: ribavirin and HBV treatment nodes share interferon-based hepatitis pathway proximity in the KG, not a direct mechanistic or clinical link. Ribavirin is an RNA-targeted antiviral; HBV is a partially double-stranded DNA virus requiring reverse-transcriptase-targeting agents (tenofovir, entecavir). Not one retrieved clinical trial enrolled HBV monoinfection patients for ribavirin treatment, and literature spanning 2000–2020 consistently places ribavirin outside HBV treatment guidelines. Proceeding with development would require building an evidence base essentially from scratch against a target where biological rationale is weak.

To proceed, the following is needed:

Preclinical HBV validation: In vitro evidence of ribavirin activity against HBV replication (IMPDH inhibition theoretically depletes GTP available for HBV cccDNA transcription — this requires experimental testing, currently absent)
Philippine FDA package insert acquisition: Full contraindication and warning profile, particularly regarding teratogenicity (Pregnancy Category X) and hemolytic anemia risk
Drug interaction (DDI) profile: DDI data was not retrieved; essential before any combination evaluation with established HBV nucleos(t)ide analogs
KG subgraph review: Audit TxGNN graph to confirm whether the high score reflects interferon-pathway node overlap rather than a true drug–disease mechanistic association
Regulatory feasibility assessment: Zero Philippine registrations means any new indication would require a full de novo filing — a high barrier given the currently weak mechanistic and clinical rationale
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.